Companies / Health Care
GILD
Gilead Sciences
Biotechnology
BiotechnologyAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health73
Growth33
Profitability99
Cash generation96
Balance sheet67
Dilution control72
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)6.8%Revenue growth (FY)2.4%Revenue CAGR (3y)2.6%Gross margin78.8%Operating margin34.0%Net margin28.9%Free cash flow margin32.1%R&D / revenue19.7%Stock comp / revenue3.0%Net debt / operating cash flow2.01xCurrent ratio1.55Diluted share count change0.0%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Gross profit | $20.7B | $21.6B | $20.6B | $22.5B | $23.2B |
| Operating income | $9.9B | $7.3B | $7.6B | $1.7B | $10.0B |
| Net income | $6.2B | $4.6B | $5.7B | $480M | $8.5B |
| Operating cash flow | $11.4B | $9.1B | $8.0B | $10.8B | $10.0B |
| Capital expenditure | $579M | $728M | $585M | $523M | $563M |
| Free cash flow | $10.8B | $8.3B | $7.4B | $10.3B | $9.5B |
| R&D | $4.6B | $5.0B | $5.7B | $5.9B | $5.8B |
| Stock-based comp | $635M | $637M | $766M | $835M | $894M |
| Buybacks | $546M | $1.4B | $1.0B | $1.1B | $1.9B |
| Dividends | $3.6B | $3.7B | $3.8B | $3.9B | $4.0B |
| Cash | $5.3B | $5.4B | $6.1B | $10.0B | $7.6B |
| Total debt | $28.2B | $27.5B | $26.8B | $28.5B | $27.7B |
| Equity | $21.1B | $21.2B | $22.8B | $19.3B | $22.7B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.